Previous Page Next Page

Trials are underway to assess benefit of veliparib combination therapies in NSCLC. A phase II study reported preliminary activity with veliparib compared with placebo in combination with carboplatin and paclitaxel as first-line treatment, although the modest difference in progression-free survival did not reach statistical significance [1]. A larger phase III trial (NCT02106546) is now underway to try to show progression-free survival benefit of first-line combination veliparib versus placebo with carboplatin and paclitaxel in a larger cohort of advanced or metastatic NSCLC patients.

Veliparib in combination with whole brain radiation therapy has also been studied in patients with brain metastases in NSCLC in a phase II trial (NCT01657799), but there was no significant survival improvement versus placebo [2].

References

  1. Ramalingam SS, Blais N, Mazieres J et al. Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 2017; 23: 1937-1944.
  2. Chabot P, Hsia TC, Ryu JS et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol 2017; 131: 105-115.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings